Introduction
============

Although, the pathogenesis of non-alcoholic steatohepatitis (NASH) is multifactorial \[[@B1]-[@B4]\], strong evidence of clinical observations \[[@B5],[@B6]\]and animal models\[[@B7],[@B8]\] indicated that inflammatory activation clearly plays a pivotal role in the disease progression. Chronic inflammation interplaying with increased oxidative stress, cytokine production, direct \"lipotoxicity\", and autoimmunity, is implicated in NAFLD pathophysiology by increasing NASH, fibrosis, and insulin resistance\[[@B9],[@B10]\]. Patients with NASH have generally significantly higher levels of serum TNF-α and IL-6 than seen in patients with simple steatosis\[[@B11],[@B12]\]. Furthermore, the expression of cytokines is higher in those patients with more severe NASH. Among the proinflammatory molecules, TNF-α has been proposed to be the key link between obesity and insulin resistance\[[@B13]\]. Thus, therapeutic strategies that directly target inflammatory pathway or secondarily alter the inflammatory process may influence both histological manifestations and systemic inflammatory state in patients with NASH.

There is currently no FDA approved available treatment for NASH. In recent years, the anti-TNF alpha agent pentoxifylline has been considered for treatment of NASH\[[@B14]-[@B16]\]. Pentoxifylline is a non-selective phosphodiesterase inhibitor reported to decrease TNF-α gene transcription as well as affecting multiple steps in the cytokine/chemokine pathway by direct or indirect inhibition of TNF-α\[[@B17]-[@B19]\]. It is necessary to examine the current state of limitation and beneficial effect of the treatment with pentoxifylline in patients with NAFLD or NASH and generating hypotheses for future research. However, we could not find any systematic reviews or meta-analyses addressing the issue. Therefore, the purpose of the research synthesis is to summarize the efficacy and safety of pentoxifylline for NASH in terms of plasma cytokines, aminotransferase, liver histopathology and adverse events.

Methods
=======

Literature Sources and Search
-----------------------------

We searched under Google, Cochrane, MEDLINE, and EMBASE and the Chinese Biomedical data bases for studies restricted to pentoxifylline treatment in humans with NAFLD/NASH in all languages until June 2010. Figure [1](#F1){ref-type="fig"} shows our search strategy. We also searched the abstracts of Annual Meeting of the American and European Association for the Study of Liver in 2009 and 2010.

![**Search strategy and results**. We use the Fatty liver as the MeSH term and list all known synonyms as free-text, 11604 references were searched totally. Combined search for all MeSH and free-text searches, 132 references were identified. Of these, we excluded 122, because they were animal experiments, nonclinical, or clearly irrelevant. Of the remaining 10 references, 4 were excluded because they did not meet our inclusion criteria. Finally, 6 references were identified (2 randomized trials and 4 prospective cohort studies) in the Figure 1 explained section.](1476-511X-10-49-1){#F1}

A separate search filtering for meta-analysis and clinical reviews yielded zero articles.

Data Extraction and Outcome Definition
--------------------------------------

For each trial, the data was gathered on the following characteristics (Table [1](#T1){ref-type="table"}.):

###### 

Characteristics of 6 Trials on pentoxifylline in subjects with NAFLD

  Source                         Methodological quality                             Diagnosis   Pentoxifylline/Control (numbers)   Interventions                                                                                                                           Outcome
  ------------------------------ -------------------------------------------------- ----------- ---------------------------------- ------------------------------------------------------------------------------------ -------------------------------------------------- ---------------------------------------
  LeeYin-Mei, 2008\[[@B20]\]     Randomized and placebo-controled                   NASH        11/9                               Pentoxifylline (1200 mg/day for 12 weeks) plus low-calorie diet and daily exercise   Placebo plus low-calorie diet and daily exercise   AST, ALT, IL-6, TNF-a, adverse events
  Buranawati W, 2007\[[@B21]\]   Randomized and placebo-controled                   NASH        16/16                              Pentoxifylline (1200 mg/day for 12 weeks) plus low-calorie diet                      Placebo plus low-calorie diet                      AST, ALT, TNF-a
  Tuncer I, 2003\[[@B22]\]       Prospective cohort study with concurrent control   NAFLD       10/10                              pentoxifylline (20 mg/kg/day for 24 weeks)                                           ursodeoxycholic acid                               AST, ALT
  Georgescu, EF 2007\[[@B23]\]   Prospective cohort study with concurrent control   NASH        13/13                              Pentoxifylline (800 mg/day for 30 weeks)                                             Ursodeoxycholic acid                               ALT, IL-6, TNF-a, Histology
  Adams 2004\[[@B24]\]           Prospective cohort study with historical control   NASH        20                                 Pentoxifylline (1,600 mg/day) for 12 months                                                                                             Adverse events
  Satapathy SK 2007 \[[@B25]\]   Prospective cohort study with historical control   NASH        9                                  Pentoxifylline (1200 mg/day for 12 months)                                                                                              Histology

1\. NAFLD/NASH: diagnosed on persistently elevated aminotransferas \> 1.5 times, plus liver biopsy and/or imaging techniques;

2\. Type of studies: randomized and controlled trials, or prospective cohort studies with a control (concurrent or historical) group;

3\. Pentoxifylline was administered at any dose, duration, and given singly or in combination versus placebo or other interventions. Co-interventions were allowed if used equally in both intervention arms of the trial.

Disagreements were resolved through consensus. Primary investigators were contacted if data were incomplete.

### Primary outcomes

1\. Mean change from baseline of ALT, AST levels and cytokines.

2\. Histological response (number of patients with histological improvement/deterioration and changes in the degree of fatty liver infiltration, inflammation, and fibrosis) based on the Brunt system or its modifications\[[@B26],[@B27]\].

### Secondary outcomes

Safety and tolerability of pentoxifylline (any adverse events as reported in trials) in patients with NAFLD or NASH.

Assessment of Methodological Quality and Statistical Analysis
-------------------------------------------------------------

The quality of the trials eligible for inclusion in the review were assessed by four (Wenjun Li, Liu zheng, Liu qing and Qu Shen) independent reviewers. Subsequently, other investigators and these four reviewers confirmed whether eligible studies met the inclusion criteria and independently assessed the accuracy of data extraction. If necessary, conflict was resolved by consensus of all investigators. The randomized, controlled trials were considered as high-quality evidence, prospective cohort studies with a concurrent control group as intermediate-quality evidence, and studies with a historical control group as low quality evidence. None of retrospective cohort studies was found.

Data was analyzed using the RevMan 5 provided by The Cochrane Collaboration. The results of the primary outcomes: mean change from baseline of ALT, AST levels and cytokines are presented as weighted mean differences (WMD) with 95% confidence intervals (CI). We used a fixed-effect model with the significant level set at P value = 0.05. Heterogeneity was explored by chi-squared test with significance set at P value ≤ 0.10 and the quantity of heterogeneity was measured by I^2^. Furthermore, a sensitivity analysis on the impact of the four excluded trials was performed in both the experimental and control study groups. For the secondary outcomes (safety and tolerability of Pentoxifylline) and histological response, we adopted available case analysis.

Results
=======

Identification of Eligible Trials
---------------------------------

Six studies met the specified criteria for assessment of ALT, AST and cytokines (table [1](#T1){ref-type="table"}). Only two studies (Yin-Mei Lee and Buranawati W) are randomized double-blind, placebo-controlled trials\[[@B20],[@B21]\]. Four prospective cohort studies with control groups includes two concurrent controls \[[@B22],[@B23]\] and two historical controls\[[@B24],[@B25]\]. In addition, two trails \[[@B24],[@B25]\]with historical controls was not involved in the analysis of ALT, AST, and cytokines, but histology and adverse events information was extracted from them\[[@B24],[@B25]\].

Characteristics of Patients and Interventions
---------------------------------------------

Six trials included 117 patients with biopsy proven NASH (n = 97) or NAFLD with high ALT and AST plus US or biopsy (n = 20). Combination of studies resulted in 48 total patients for the control group(25 for Placebo plus low-calorie diet or daily exercise, 23 for ursodeoxycholic acid alone)and 79 patients for the pentoxifylline group(27 pentoxifylline plus a low-calorie diet or daily exercise and 52 pentoxifylline alone). All trials used at a dose of 800 mg to 1600 mg per day for 3-6 months. Inclusion Criteria: Male and female patients ages 18 to 70 years; daily alcohol intake of \< 20 g; appropriate exclusion of other liver diseases and positive testing for hepatitis B surface antigen, hepatitis C virus antibody, or RNA of hepatitis C virus and DNA of hepatitis B virus.

Effects on Serum Aminotransferase
---------------------------------

Liver function response was assessed by serum activities of AST and ALT. AST activity was evaluated in all included trials, however, Placebo or UDCA-Controlled studies were reported only in three trials, including two randomized studies\[[@B20],[@B21]\] and one prospective study \[[@B22]\]. Pentoxifylline-treated patients showed a significant decrease (P = 0.01) in AST activity (weighted mean differences (WMD) -6.11 IU/L, 95% CI -10.78 to -1.44) versus control-treated patients. Heterogeneity was high, but not statistically significant (I^2^= 30%, *P*= 0.24)(Figure [2](#F2){ref-type="fig"}).

![**Overall summary of meta-analyses results of treatments of pentoxifylline for NASH**. Pentoxifylline-treated patients showed a significant decrease AST (n = 37, *P*= 0.01) and ALT (n = 50, *P*= 0.03), but no significant effect on IL-6 (n = 36, *P*= 0.33) and TNF-α (n = 68, *P*= 0.26) compared with Placebo or UDCA-controlled groups.](1476-511X-10-49-2){#F2}

ALT activity was evaluated in all four Placebo or UDCA-Controlled trials\[[@B20]-[@B23]\]. There were significant differences between pentoxifylline and control treatment (P = 0.03, WMD was -6.44 IU/L, 95% CI -12.26 to 0.62). Intertrial heterogeneity was not statistically significant (*P*= 0. 18) (Figure [2](#F2){ref-type="fig"}).

Effects on Cytokines
--------------------

IL-6 and TNF-α were able to be extracted from 2 Placebo \[[@B20],[@B21]\] and 1 UDCA-controlled trials \[[@B22]\]. Meta-analyses of these data indicated that pentoxifylline had no significant effect on IL-6 (*P*= 0.33, WMD = -1.12, 95% CI: -3.39, -1.15) and TNF-α (*P*= 0.26, WMD = -1.58, 95% CI: -4.32, -1.16). In these analyses, intertrial heterogeneity was not statistically significant (*P*= 0.89 and *P*= 0.32, respectively) (Figure [2](#F2){ref-type="fig"}).

Histological Response
---------------------

Two trials \[[@B23],[@B25]\] have assessed the histological response that evaluated the scores of steatosis, inflammation/necrosis, and fibrosis before and after treatment. After 12 months of therapy with pentoxifylline, significant overall improvement of liver histology was reported in Satapathy SK\'s study. Sixty seven percent of patients had a decrease in overall grading based on Brunt\'s staging (*P*= 0.009). Fifty-five percent of the patients had a reduction in their steatosis and lobular inflammation (RR, 0.06: 95% CI, 0.00 to 1.43). Four out of the six patients with baseline fibrosis had a reduction in their fibrosis stage (3 had one stage reduction and 1 patient had a two stage reduction), and another two patients remained stable on follow-up biopsy. In Georgescu\'s study, each histological variable before and after treatment was significantly diminished from 2.231 to 1.462 for steatosis score, from 1.692 to 1.231 for the lobular inflammation score, from 1.308 to 1.154 for hepatocyte ballooning score and from 1.308 to 1.077 for fibrosis score None of these scores changed significantly in the placebo and UDCA group.

Adverse events
--------------

Among the six trials, two \[[@B20],[@B24]\] provided information on adverse events. In Adams\'s trial \[[@B24]\], nine of 20 patients withdrew from the study, primarily because of nausea, but no serious adverse events occurred. One explanation for the significant drop out rate in the study is probably due to a higher dose of pentoxifylline used (1,600 mg/day). Pentoxifylline was well tolerated at a dose of 1,200 mg/day for six months and no adverse events and none was lost to follow-up in the trial \[[@B20]\]

Discussion
==========

Pentoxifylline has been safely used for the treatment of other medical conditions such as alcohol related liver disease. Pentoxifylline-treated patients have a significant mortality and hepatorenal syndrome improvements \[[@B28]\]. Individual studies and pilot trials of pentoxifylline in nonalcoholic steatohepatitis have suggested that anti-inflammatory therapy had effectively biochemical improvement and cytokine-mediated systemic inflammation amelioration (i.e., reduced plasma TNF-α and IL-6 levels). These results serve as \"proof of concept\" that pentoxifylline has efficacy in patients with nonalcoholic steatohepatitis, but the overall benefits of this approach have not been fully assessed quantitatively.

Improved liver aminotransferase levels are consistent evidence from all trails in the research synthesis. Pentoxifylline reduced significantly ALT and AST levels in patients with NASH compared to the placebo or UDCA groups. Increased liver enzymes are usually thought to be a consequence of liver injury in NAFLD, and improvement in liver enzymes can possibly be used as predictors of NAFLD improvement\[[@B29]\]. However, some studies have shown that a significant proportion of patients with normal ALT also had steatohepatitis and fibrosis on liver biopsy\[[@B30]-[@B32]\], indicating that aminotransferase per se cannot be used as a surrogate marker to assess the significant potential in therapies in patients with NASH.

Histological response was assessed only by Satapathy SK and Georgescu EF\[[@B25],[@B23]\]. Both studies evaluated the scores of steatosis, inflammation/necrosis, and fibrosis before and after treatment. Improvement in one or more histological variables was noticed only in pentoxifylline subgroup, but not in the UDCA subgroup in the Georgescu EF\'s study. A significant reduction in steatosis, ballooning and lobular inflammation was also observed in the Satapathy SK\'s study. It was interestingly to be noted that pentoxifylline had a reduced baseline fibrosis stage in four out of the six patients, including 3 patients had one stage and a single patient had a two stage reduction \[[@B25]\]. Because fibrosis may progress in up to one third of patients with nonalcoholic steatohepatitis, regardless of whether hepatic aminotransferases improves or worsens, the antifibrotic effects of pentoxifylline should surely be an important issue. The overall methodological quality of the studies included in this issue was relatively weak and some bias may exist. Both are prospective studies with a historical \[[@B25]\] or a concurrent \[[@B23]\] control group, thus the true benefits may not be as extreme as reported here.

As an anti-TNF agent, pentoxifylline may be valuable in amelioration of cytokine-mediated systemic inflammation in patients with NASH. However, there was no significant difference in the reduction of TNF-α and IL-6 between the pentoxifylline and the control groups\[[@B20]-[@B22]\]. Because of a lack of comprehensive data in most studies, we could not reliably assess these factors. An protocol of ongoing trial by Mary ER et al\[[@B33]\] is available online, which assess the effect of pentoxifylline on adipocyte-derived cytokines, leptin and adiponectin, and its effect on free fatty acid levels in patients with NASH, but we was not able to find the final report.

Despite the limitations of the studies included in this review, it seems to suggest that pentoxifylline therapy had a beneficial effect on liver aminotransferase levels and histology improvements (reductions in steatosis, inflammation, and ballooning necrosis). Large, prospective, and well-designed randomized, controlled studies are needed to address this issue. It will probably be important to design specific anti-inflammatory approaches for different types and stages of NAFLD subgroups\[[@B34]\]. In addition, novel \'anti-inflammatory\' targets evolving from basic research, such as activation of inflammatory signaling pathways by fat, in particular IKK and JNK, or Foxo1, also merit investigation\[[@B35]\].
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